Theriva Biologics: second IDMC review finds VCN-01 well tolerated in metastatic PDAC trial

Theriva Biologics, Inc.

IDMC reviewed safety data from 101 patients across 14 sites in US and Spain.
VCN-01 AE profile consistent with prior trials; AEs transient and reversible, less frequent after second dose.
Patient enrollment completed Sep 2024; topline clinical outcomes data expected Q2 2025.
CEO says positive data, along with prior FDA/EMA feedback, could guide Phase 3 registrational trial design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.